Research reveals the gut microbiota-brain axis as a critical link in understanding and treating neurological disorders through microbial interventions.
Sarepta touts Duchenne gene therapy uptake, but warns of demand flattening before potential expanded label from FDA
Sarepta Therapeutics announced Wednesday afternoon that its Duchenne muscular dystrophy gene therapy Elevidys pulled in $200 million in its first half-year on the commercial market.
March 1, 2024